|
Product Name: | MTI-31 | Synonyms: | MTI-31;Benzamide, N-methyl-3-[2-[(3S)-3-methyl-4-morpholinyl]-4-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)pyrido[2,3-d]pyrimidin-7-yl]-;LXI-15029;mTOR kinase inhibitor,tissue factor,mTORC2,mTOR inhibitor,Inhibitor,EGFR mutant cancer,mTOR-TF axis,Mammalian target of Rapamycin,apoptosis,MTI 31,mTOR,inhibit,MTI31,mTORC1,lipid metabolism,tumor microenvironment;HTH-01-091 TFA;N-methyl-3-{2-[(3S)-3-methylmorpholin-4-yl]-4-{3-oxa-8-azabicyclo[3.2.1]octan-8-yl}pyrido[2,3-d]pyrimidin-7-yl}benzamide | CAS: | 1567915-38-1 | MF: | C26H30N6O3 | MW: | 474.55 | EINECS: | | Product Categories: | | Mol File: | 1567915-38-1.mol | |
| MTI-31 Chemical Properties |
density | 1.275±0.06 g/cm3(Predicted) | storage temp. | Store at -20°C | solubility | DMSO : 8.33 mg/mL (17.55 mM; ultrasonic and warming and heat to 60°C) | form | Solid | pka | 14.45±0.46(Predicted) | color | White to yellow |
| MTI-31 Usage And Synthesis |
| MTI-31 Preparation Products And Raw materials |
|